InsidersTradesSigma
Track the Summit Therapeutics Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Summit Therapeutics Inc. has published 32 public disclosures. Market capitalisation: €10.7bn. The latest transaction was disclosed on 23 October 2025 (Acquisition). Among the most active insiders: Zanganeh Mahkam. Every trade is accessible without an account.
32
Insider Decl.
n/a
Thresholds
€519m
15 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Summit Therapeutics Inc. Buy (bullish), based on 13 analysts. Average price target: US$28.80.
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 October 2025
Declarations32 total
26,680 shares@ US$18.7448.7% of flowCommon StockSEC:0001890784-25-000005:0
53,361 shares@ US$18.7413.2% of flowCommon StockSEC:0001569769-25-000002:0
266,808 shares@ US$18.748.6% of flowCommon StockSEC:0001507650-25-000003:0
13,980,789 shares@ US$18.7429.4% of flowCommon StockSEC:0001055919-25-000003:0
333,394 shares@ US$17.6811.0% of flowCommon StockSEC:0001599298-25-000143:0
Canonical exit: 9 Dec 2025 (T+90)
333,394 shares@ US$17.680.9% of flowCommon StockSEC:0001599298-25-000142:0
Canonical exit: 9 Dec 2025 (T+90)
74,545 shares@ US$2.640.4% of flowCommon StockSEC:0001599298-25-000107:0
74,545 shares@ US$2.640.0% of flowCommon StockSEC:0001599298-25-000106:0
3,985,055 shares@ US$1.581.1% of flowCommon StockSEC:0001599298-25-000058:0
3,985,055 shares@ US$1.5814.2% of flowCommon StockSEC:0001599298-25-000060:0
315,681 shares@ US$1.581.1% of flowCommon StockSEC:0001599298-24-000146:0
44,052 shares@ US$22.70100.0% of flowCommon StockSEC:0001599298-24-000138:0
3,325,991 shares@ US$22.7012.8% of flowCommon StockSEC:0001599298-24-000139:0
44,052 shares@ US$22.7016.1% of flowCommon StockSEC:0001599298-24-000136:0
44,052 shares@ US$22.702.2% of flowCommon StockSEC:0001599298-24-000141:0
22,026 shares@ US$22.70100.0% of flowCommon StockSEC:0001599298-24-000135:0
100,000 shares@ US$3.7561.4% of flowCommon StockSEC:0001599298-24-000046:0
Canonical exit: 24 Jun 2024 (T+90)
26,000 shares@ US$3.720.2% of flowCommon StockSEC:0001599298-24-000047:0
Canonical exit: 25 Jun 2024 (T+90)
700 shares@ US$2.150.2% of flowCommon StockSEC:0001599298-23-000101:0
Canonical exit: 12 Mar 2024 (T+90)
489,814 shares@ US$1.441.6% of flowCommon StockSEC:0001599298-23-000103:0
2,976,190 shares@ US$1.6883.9% of flowCommon StockSEC:0001569769-23-000007:0
Canonical exit: 11 Jan 2024 (T+90)
16,778,415 shares@ US$1.0541.3% of flowCommon StockSEC:0001387131-23-003381:0
Canonical exit: 6 Jun 2023 (T+90)
196,362 shares@ US$1.0534.2% of flowCommon StockSEC:0001849682-23-000004:0
Canonical exit: 5 Jun 2023 (T+90)
15,973,743 shares@ US$1.0539.3% of flowCommon StockSEC:0001599298-23-000028:0
Canonical exit: 6 Jun 2023 (T+90)
25 of 32 declarations
关于 Summit Therapeutics Inc.
Summit Therapeutics Inc.（股票代码：SMMT）是一家在美国纳斯达克市场交易的美国上市生物制药公司。Summit总部位于佛罗里达州迈阿密，在医疗保健和制药领域运营，明确专注于肿瘤学。其商业模式以发现、开发并最终商业化旨在解决严重未满足医疗需求的创新药物为中心。对于投资者而言，Summit应主要被视为一家临床阶段生物技术公司：价值创造由临床执行、试验结果和监管里程碑驱动，而非广泛的上市产品组合。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000015/smmt-20251231.htm?utm_source=openai)) 公司起源于2003年。随着时间的推移，Summit从一个更广泛的研发组织演变为一个更专注的肿瘤学开发商，调整其战略，将资本和管理层的注意力集中在具有最高科学和商业潜力的项目上。其美国公司结构在2020年得到进一步加强，当时Summit Therapeutics Inc.成为美国市场的主要继承发行人。这段历史很重要，因为它解释了为什么当前的投资案例是集中的、高风险的，并且高度依赖于一小部分资产，而不是多元化的商业平台。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/summittherapeutics20fdec20.htm?utm_source=openai)) 目前，Summit故事的核心是ivonescimab，一种在其区域内获得许可的在研双特异性抗体，在Summit许可区域内被称为SMT112。公司主要在非小细胞肺癌（NSCLC）领域推进其管线，开展了多项全球III期研究，包括HARMONi、HARMONi-3、HARMONi-6和HARMONi-7。实际上，Summit是一家以单一资产为主导的肿瘤生物技术公司：如果该资产成功，这种集中可以放大上行空间，但如果数据令人失望，也会带来重大的二元临床和监管风险。（[businesswire.com](https://www.businesswire.com/news/home/20250811380438/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-Ended-June-30-2025?utm_source=openai)) 从竞争角度来看，Summit正在现代生物技术中最拥挤和战略上最重要的领域之一运营：肺癌免疫疗法和靶向联合开发。其差异化取决于ivonescimab的临床特征、全球试验中生成的数据集的质量，以及将这些结果转化为监管和商业吸引力的能力。从地理上看，Summit具有国际范围，其美国公司运营和临床/合作活动遍及多个地区，包括欧洲和亚洲。公司还通过合作协议扩展了其开发框架，包括与Revolution Medicines的合作。（[finance.yahoo.com](https://finance.yahoo.com/news/summit-therapeutics-reports-financial-results-104500313.html?utm_source=openai)) 近期公司更新主要集中在ivonescimab的临床进展、更广泛的III期开发，以及根据不断演变的数据包可能进行的美国监管备案的时间。对于股票投资者而言，这意味着Summit仍然是一个对新闻敏感的生物技术公司：股价表现可能对试验更新、FDA相关评论以及在SEC Form 4上提交的内部人交易披露做出剧烈反应。结果是，该股票符合高上行空间但高波动性的肿瘤催化剂故事的特征。（[tradingview.com](https://www.tradingview.com/news/reuters.com%2C2025%3Anewsml_L6N3S20I5%3A0-summit-therapeutics-falls-after-mixed-data-from-late-stage-cancer-trial/?utm_source=openai))
